University of Sheffield appoints Cobra to advance growth hormone antagonist
23 November 2015 | By Victoria White
Cobra will be using its cell line development service, maxXpress, to produce the growth hormone antagonist fusion protein...
List view / Grid view
News
Cocktail of mutant proteins linked to Huntington’s disease
20 November 2015 | By Victoria White
Researchers have shown that the gene that causes Huntington's diseases makes an unexpected "cocktail" of mutant proteins that build up in regions of the brain that are most affected by the disease...
AstraZeneca invests in its Cambridge lead discovery centre
20 November 2015 | By Victoria White
The company has announced three new partnerships that will deliver a collaborative screening platform, space-age robotics, and sound waves that can move liquids...
Intelligent biogel effective at delivering anti-cancer agents
20 November 2015 | By Victoria White
The technology has already been successfully tested in the laboratory. If it works in patients, the therapy could one day revolutionise treatment for many forms of cancer...
Sanofi and AstraZeneca exchange 210,000 chemical compounds
20 November 2015 | By Victoria White
The compound exchange represents a novel, open innovation model of collaboration between the two companies.
FDA clears first-in-human clinical study for MERS vaccine
19 November 2015 | By Victoria White
GeneOne Life Science and Inovio are co-developing the vaccine and plan to initiate the first human trial of a MERS vaccine before the end of the year...
Presence of protein aggregates as important as form in cell death
19 November 2015 | By Victoria White
Scientists have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue...
Gamma interferon protects mice from Ebola
19 November 2015 | By Victoria White
A new study suggests that gamma interferon, which is an FDA-approved drug, may have potential as an antiviral therapy to prevent Ebola infection when given either before or after exposure to the virus...
York scientists reveal structure of heparanase
19 November 2015 | By Victoria White
Researchers have unveiled the 3-D structure of human heparanase - a sugar-degrading enzyme which has received significant attention as a key target in anti-cancer treatments...
‘Good’ mosquito virus could hold the key to fighting disease
18 November 2015 | By Victoria White
The newly discovered virus, known as Parramatta River virus, infects only mosquitoes and does not pose any direct health risks to people...
miR-124 reduces tumour growth in advanced prostate cancer
18 November 2015 | By Victoria White
miR-124 hit multiple targets, reducing androgen receptor signalling and reviving the potency of advanced prostate cancer treatment Xtandi (enzalutamide)...
TSRI scientists use trait of anti-HIV antibodies to develop vaccine candidates
18 November 2015 | By Victoria White
When studying prototype antibodies that target a specific weak spot on HIV, the researchers noted two of the antibodies had an unusual feature that could prove important in vaccine design...
Morphotek and Univeristy of Gothenburg to develop farletuzumab
18 November 2015 | By Victoria White
Morphotek and the TAT Group will investigate farletuzumab as an alpha therapy vector for radioimmunotherapy in ovarian cancer...
DBV Technologies presents data on its Viaskin technology in RSV
18 November 2015 | By Victoria White
DBV Tecnologies observed an immunogenic response in mice and swine treated with Viaskin with a patented formulation containing an N-FsII antigen...
UCLA researchers identify drug that helps fight side effect of ovarian cancer
17 November 2015 | By Victoria White
The researchers found that a drug that inhibits a receptor called the Colony-Stimulating-Factor-1 Receptor reduces ascites with minimal side effects...
